玉屏风散治疗变应性鼻炎：一项对照试验系统评价方案
Okbyungpoongsan (Yupingfeng) for treating allergic rhinitis: A protocol for the systematic review of controlled trials.
作者信息
Lee Minseong, Kim Youngjo, Lee Ju Ah
机构信息
College of Korean Medicine, Gachon University, Seongnam, Korea.
出版信息
Medicine (Baltimore). 2018 Nov;97(45):e13227. doi: 10.1097/MD.0000000000013227.
BACKGROUND
Okbyungpoongsan (OBPS) is widely used as a treatment for allergic rhinitis (AR) in Far East countries. Many clinical trials have assessed the efficacy and safety of the OBPS formula for treating AR. Here, we systematically will review the clinical evidence for and against administration of OBPS.
METHODS AND ANALYSIS
All RCTs of decoctions or modified decoctions will be included. The methodological quality of the RCTs will be analyzed using the Cochrane Collaboration tool for assessing risk of bias, while confidence in the cumulative evidence will be evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) instrument.
ETHICS AND DISSEMINATION
This systematic review will be published in a peer-reviewed journal and will also be disseminated electronically and in print. The review will be updated to provide additional information and guide healthcare practices.Registration number: CRD42017080292.
背景
玉屏风散（OBPS）在远东国家被广泛用于治疗过敏性鼻炎（AR）。许多临床试验评估了玉屏风散配方治疗AR的疗效和安全性。在此，我们将系统回顾支持和反对使用玉屏风散的临床证据。
方法与分析
将纳入所有关于汤剂或改良汤剂的随机对照试验（RCT）。使用Cochrane协作网评估偏倚风险的工具分析RCT的方法学质量，同时使用推荐分级评估、制定与评价（GRADE）工具评估对累积证据的可信度。
伦理与传播
本系统评价将发表在同行评审期刊上，也将以电子和印刷形式传播。该评价将更新以提供更多信息并指导医疗实践。注册号：CRD42017080292。
Zotero 插件